Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium animalis lactis is a probiotic strain that has received moderate scientific attention for its potential to alleviate constipation in children. Several randomized controlled trials (RCTs) have investigated the effects of B. animalis lactis supplementation on pediatric constipation. For instance, a notable study published in JAMA Pediatrics (2017) found that children aged 4-16 with functional constipation who received B. animalis subsp. lactis DN-173 010 daily did not experience a significant improvement in defecation frequency compared to placebo, although some secondary outcomes (such as stool consistency) showed minor improvements. Other studies, such as a 2015 trial in Pediatrics, reported similar modest benefits, with increased stool frequency and softer stools in children receiving B. animalis lactis compared to controls.

Systematic reviews and meta-analyses have generally concluded that while there is some evidence supporting the efficacy of B. animalis lactis in improving certain constipation-related symptoms (such as stool frequency and consistency), the effects are modest and not consistently demonstrated across all studies. No serious adverse effects have been reported, indicating a favorable safety profile. Most clinical guidelines do not currently recommend probiotics, including B. animalis lactis, as a first-line therapy for pediatric constipation, but acknowledge their potential as adjunctive measures.

In summary, use of B. animalis lactis for pediatric constipation is supported by moderate scientific evidence, with some clinical trials and reviews suggesting mild benefit, but results are inconsistent and further high-quality studies are needed.

More about Bifidobacterium animalis lactis
More about Constipation (children)

Other ingredients used for Constipation (children)

Other health conditions supported by Bifidobacterium animalis lactis

Products containing Bifidobacterium animalis lactis